Clinical evaluation of recombinant human interferon-α-2b gel combined with pidotimod for the treatment of low-grade squamous intraepithelial lesions of the cervix
Clinical evaluation of recombinant human interferon-α-2b gel combined with pidotimod for the treatment of low-grade squamous intraepithelial lesions of the cervix
Objective To evaluate the clinical efficacy of recombinant human interferon-α-2b gel combined with pidotimod in treating cervical low-grade squamous intraepithelial lesions(LSIL/CIN1).Methods This study included 88 patients with LSIL/CIN1 admitted to the Second People's Hospital of Liaocheng from January 2020 to January 2024.Patients were randomly divided into a control group(n=44,treated with recombinant human interferon-α-2b gel)and a PID group(n=44,receiving pidotimod in addition to the control group treatment).Clinical efficacy,vaginal microecology,immune function,inflammatory levels in lavage fluid,and incidence of adverse reactions were compared between the two groups.Results The total effective rate in the PID group was higher than that in the control group(P<0.05).The recovery rate of vaginal microecology in the PID group was greater than that in the control group(P<0.05).The vaginal secretion pH and Nugent score in the PID group were lower than those in the control group(P<0.05).The differences in CD4+,CD8+,Treg,and Th17 levels before and after treatment were greater in the PID group compared to the control group,with a significant increase in CD4+levels and a notable decrease in CD8+,Treg,and Th17 levels(P<0.05).The differences in IFN-γ,IL-10,and TNF-α levels before and after treatment were also higher in the PID group,with a significant increase in IFN-γ and a notable decrease in IL-10 and TNF-α compared to the control group(P<0.05).No significant difference was found in the incidence of adverse reactions between the two groups(P>0.05).Conclusion The combination of recombinant human interferon-α-2b gel and pidotimod is effective in improving immune levels and reducing inflammation in patients with LSIL/CIN1,with good safety and suitability for widespread clinical application.
关键词
宫颈低级别鳞状上皮内病变/重组人干扰素α-2b/匹多莫德/炎症标志物/安全性
Key words
cervical low-grade squamous intraepithelial lesion/recombinant human interferon-α-2b/pidotimod/inflammatory markers/safety
维普
万方数据